RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-5045
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1025100; Gene model (P.falciparum): PF3D7_1417600; Gene product: conserved Plasmodium protein, unknown function (oocyst capsule protein (OSCP))
Phenotype Fertilization and ookinete; Oocyst; Sporozoite; Liver stage;
Last modified: 28 July 2021, 16:45
  *RMgm-5045
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption
Reference (PubMed-PMID number) Reference 1 (PMID number) : 34289894
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherNakayama K, Ikadai H
Name Group/DepartmentLaboratory of Veterinary Parasitology, School of Veterinary Medicine
Name InstituteKitasato University
CityTowada, Aomori
CountryJapan
Name of the mutant parasite
RMgm numberRMgm-5045
Principal nameOSCP-KO
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNormal numbers of ookinetes are formed with wild-type morphology. Evidence is provided for reduced gliding motility of ookinetes.
OocystEvidence is provided for reduced gliding motility of ookinetes. Reduced oocyst production. On days 9 and 14, oocyst diameter was significantly smaller than of wild-type oocysts. Transmission electron microscopy provided evidence that on day 17 oocysts exhibited wall thinning and indistinguishable internal structures (however, sporozoites are formed; see below).
SporozoiteWhen mosquitoes were allowed to feed on naive mice 25 days after an infectious blood meal, they transmitted both WT and KO parasites, suggesting that OSCP is not essential for sporozoite function.
Liver stageWhen mosquitoes were allowed to feed on naive mice 25 days after an infectious blood meal, they transmitted both WT and KO parasites, suggesting that OSCP is not essential for sporozoite function.
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of OSCP

Protein (function)
OSCP (oocyst capsule protein) is predicted to have 4236 amino acids and has a molecular weight of 494 kDa. It has a predicted transmembrane domain in amino acids 97–119.

Phenotype
Normal numbers of ookinetes are formed with wild-type morphology. Evidence is provided for reduced gliding motility of ookinetes. Reduced oocyst production. On days 9 and 14, oocyst diameter was significantly smaller than of wild-type oocysts. Transmission electron microscopy provided evidence that on day 17 oocysts exhibited wall thinning and indistinguishable internal structures (however, sporozoites are formed; see below).
When mosquitoes were allowed to feed on naïve mice 25 days after an infectious blood meal, they transmitted both WT and KO parasites, suggesting that OSCP is not essential for sporozoite function.

Additional information
The IFA images comparing ookinetes fixed with PFA and TritonX-100 treatment, fixed with PFA and no TritonX-100 treatment, and unfixed (live) parasites provided evidence that OSCP was expressed on the ookinete surface. PbCap380 is a surface protein of the oocyst capsule, and the IFAs of day 15 oocysts using anti-OSCP and anti-PbCap380 antibodies indicated that OSCP colocalizes with PbCap380.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1025100
Gene Model P. falciparum ortholog PF3D7_1417600
Gene productconserved Plasmodium protein, unknown function
Gene product: Alternative nameoocyst capsule protein (OSCP)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr
Promoter of the selectable markerunknown
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6